Evofem rises on drug development collaboration with Canada's Orion

Evofem Biosciences

16/12/2021 13:39

** Shares of women's health drugmaker  EVFM.O  up ~10% at
$0.417 premarket
    ** Co and Orion Biotechnology Canada Ltd enter into
partnership to test compatibility and stability of Orion's drug
candidate, OB-002, in co's vaginal gel product, Phexxi
 urn:newsml:reuters.com:*:nPn7n0qtMa 
    ** The goal is to develop a Multipurpose Prevention
Technology (MPT) product candidate for indications including the
prevention of HIV in women 
    ** This collaboration is expected to yield results in Q3
2022 - co 
    ** Upon positive results, cos will seek government and
philanthropic funding for subsequent clinical trials of MPT
vaginal gel product candidate
    ** Up to Wednesday's close, stock had fallen 84.23% YTD 

 (Reporting by Oishee Majumdar in Bengaluru)
 ((oishee.majumdar@thomsonreuters.com;))